The unique biological and clinical features of 11q23 associated leukemias, in conjunction with their induction by altered versions of ALL-1, a highly intricate chromatin modifier (9) , prompted us to look for molecular clues for those features by examining the expression profiles of these leukemias.
Materials and Methods
Patients and specimens. Apart from two individuals, all patients with 11q23 abnormalities were adults.
The samples were provided by GIMENA Italian Multicenter Study Group. Also included in the analysis were four AML cell lines with t(9;11) (MONOMAC6, TPH1, MOLM13 and PER377) and one with t(6;11) (ML2), and two ALL cell lines with t(4;11) -RS4;11 and B1. Genes picked up in the supervised analysis, as well as those pointed out as separating ALLs with and without t(4;11) in nonsupervised analysis, had similar expression profiles in cell lines and primary tumors. The primary tumors included 12 ALLs with t(4;11) obtained from 10 adults, one child and one infant, and 10 AMLs of adults including 5 with t(9;11), 3 with ALL-1 partial duplication and single cases of t(10;11) and t (11;19) . Controls comprised of 10 AMLs of adults, 11 ALLs of adults and 2 ALLs of children. Details regarding the patients may be found in Table 2 in PNAS web site (www.pnas.org). Bone marrow samples were obtained from newly diagnosed patients.
DNA microarray analysis. RNAs were extracted from fresh or cryopreserved mononuclear cells by using Trizol reagent (Sigma), and assessed for their integrity by gel electrophoresis. 10 µg aliquots of total RNAs were utilized to prepare biotin-labeled cRNAs according to Affymetrix protocol. These RNAs were subsequently hybridized to human U95 oligonucleotide probe arrays corresponding to 12600 sequences (genes) (Affymetrix). Arrays were scanned and the expression value for each gene was calculated using Affymetrix software. This raw expression data was re-scaled to compensate for variations between arrays in hybridization intensity.
Preprocessing and filtering of data. The expression data was organized in a matrix of n s =52 columns (hybridizations) and 12,600 rows (genes on the chip). (11) , which focuses on correlated groups of genes, one group at a time. We assume that each such group is important for one particular process of interest. Thereby the noise generated by the large majority of genes that are not relevant for that process is eliminated; furthermore, by using a group of correlated genes, noise of the individual measurements is averaged out and reduced. The relevant subsets of genes and samples are identified by means of an iterative process, which uses, at each iteration level, stable gene and sample clusters that were generated at the previous step. Before each clustering operation the rows of the data matrix (genes) are centered (mean=0) and normalized (standard deviation = 1). The ability to focus on stable clusters that were generated by any clustering operation is essential for the CTWC method; otherwise, there would be computationally unfeasible number of gene/sample cluster pairs to test (11) . Since most clustering methods do not have a reliable inherent stability measure for clusters, we used Superparamagnetic Clustering (SPC), a physics-based algorithm (12) , that does provide a stability index, T ∆ (C), to each
cluster C. SPC was tested on data from a large number of problem areas including image analysis, speech recognition, computer vision and gene expression (11,12 and ref therein) . A parameter T controls the resolution at which the data are viewed; as T increases, clusters break up, and the outcome is a dendrogram.
A cluster C is "born" at T =T 1 (C), the value of T at which its "parent" cluster breaks up into two or more subclusters, one of which is C. As T increases further, to T 2 (C) > T 1 (C), C itself breaks up and "dies"; ∆T(C)
is the stability index provided by SPC. The larger ∆T(C), the more statistically significant and stable (against noise in the data and fluctuations) is the cluster C (13). Table 1 . The complete lists may be found in Table 3 as supplementary information. The clear difference in expression profiles between ALLs with the t(4;11) abnormality and other types of ALLs establish that the former belong to a unique and distinguishable class of ALL.
Results

Expression profiles of ALLs with t(4;11). Leukemic cells of ALLs
Examination of the genes whose expression pattern distinguishes t(4;11) ALLs from other ALLs reveals a substantial number of genes associated with growth control, cell transformation or malignancy;
those genes may be classified into several functional categories:
1. overexpressed oncogenes -a) HOX A9 and MEIS1, which form a sequence specific DNA binding complex (14) , are frequently co-activated in spontaneous AML of BXH-2 mice (15). Forced co-expression of the two genes in murine bone marrow cells rapidly induces AML (16) . b) HOX A10, which induces AML in mice (17) . c) LMO2 (RMBT2), whose overexpression, resulting from chromosome translocations, is associated with T-cell ALL (18) . d) MYC, which has a critical role in cell proliferation and is deregulated in human lymphomas and other tumors (19) . e) LGALS1 (galectin1), which cooperates with RAS in cell transformation (20) and whose overexpression correlates with progression of glioblastoma (21) . f) PDGFRB 8 (platelet-derived growth factor receptor beta), which is a tyrosine kinase, and is deregulated through chromosome translocations and gene fusions in chronic myeloproliferative diseases (22).
2. overexpressed genes involved in drug resistance -a) CD44, associated with aggressive B-CLL (23) and conferring resistance to several widely-used anticancer drugs (24) . b) DHFR (dihydrofolate reductase), conferring resistance to methotraxate. c). BLMH (bleomycine hydrolase). d) CAT (catalase), which protects from oxidative stress. 6. overexpressed genes acting in cell cycle progression and cell proliferation -a) CCNA1 (cyclin A1), which functions in S phase and mitosis and its expression is elevated in a variety of tumors including AMLs (36) . b) BMYB (myb-like 2), which is required for proliferation of hematopoietic cells (37) and directly activates the anti-apoptotic gene ApoJ/clusterin (38) . c) CDKN3 (cyclin dependent kinase inhibitor 3), which interacts with cyclin dependent kinases and is overexpressed in breast and prostate cancer (39).
Our battery of ALLs lacking t(4;11) consisted of tumors at various stages of differentiation including pre B-, pro B-and T-cell ALLs. Therefore, the differences in expression found should be due in part to the differences in differentiation stage between t(4;11) to the other ALLs. Hence we now tried to: 1)
identify those genes whose expression pattern is directly correlated with the t(4;11) abnormality, either resulting from the abnormality or specifically associated with the cell type in which the chromosome translocation occurred. 2) separate the genes above from genes whose expression reflects (sensitive to) the differences between early vs late differentiation stage (pro B-vs pre B-and T-cell tumors). 3) identify genes associated with unique features of CD10 -ALLs.To this end we defined three groups of ALL samples: (i)
t(4;11) tumors (pro B-cells), (ii) CD10 -tumors (pro B-cells), and (iii) rest of the ALLs (pre B-and T-cells).
Three distinct supervised analyses were performed, which separate: 1) t(4;11) ALLs from the rest of ALLs.
2) t(4;11) ALLs from CD10 -ALLs. 3) CD10 -ALLs from the rest of ALLs.
The genes that participate in one or more separations were identified (see the Venn diagram of Fig.   2A ). Three overlapping groups were found, containing 80, 46 and 21 genes (lists of genes in Tables 4-6 samples. The three tumors also show some quantitative variation from the other t(4;11) ALLs in transcription of the genes whose expression is associated with CD10 -ALLs (genes 127-147) (Fig. 2B) .
These results suggest the existence of two sub-families of ALLs with the t(4;11) chromosome translocation, distinguished by their expression patterns.
Finally, we applied the coupled two-way clustering method (11, 12) in an unsupervised analysis. A group of 25 genes was found consistently underexpressed in ALLs with t(4;11) compared to the other ALLs ( Fig. 3 ; Table 7 in the web site). The cluster of samples with low expression of these genes includes 13/14 of t(4;11) and 3/4 of CD10 -ALLs. This is consistent with the close similarity in biological and clinical features between these two types of tumors. A second group of 132 genes separated the seven cell lines included in the analysis from the forty-five primary tumors. All these genes were underexpressed in the cell lines ( Fig. 6 and Table 8 in the web site).
Transcription profile of AMLs with ALL-1 rearrangements. AMLs with 11q23 translocations and ALL-1 rearrangements were compared in their expression profiles to AMLs with normal karyotypes. At FDR of 0.15 (85% confidence) we identified 67 genes overexpressed or underexpressed in AMLs with 11q23 abnormalities ( Fig. 4 ; Table 9 in web site). Three primary AMLs with ALL-1 partial duplication (5) were compared to the other AMLs with regard to expression of the 67 genes. Two of the three tumors resembled
AMLs without 11q23 abnormalities, while the third appeared closer to the tumors with chromosome translocations (Fig. 4) . The similarity between AMLs without 11q23 aberrations and AMLs with ALL-1 partial duplications was further evidenced in the failure to separate the two groups at an acceptable FDR.
(In parallel, AMLs with 11q23 abnormalities were separated from AMLs with ALL-1 partial duplications at FDR of 0.3; some of this analysis is shown in Fig. 7 and Table 10 Examination of the list of genes most correlated with AMLs carrying 11q23 abnormalities ( Table 9 in the web site) discloses some involved in cancer or related processes. These include the overexpressed insulin receptor which enhances DNA synthesis and inhibits apoptosis (40), the overexpressed repair gene RAD 51 which is upregulated in breast and pancreatic cancers (41) and probably increases drug resistance, the overexpressed PPP2R5C phosphatase, the underexpressed JUNB which upregulates the tumor suppressor gene p16 and represses cyclin D1 (42) and whose knockout in mice induces myeloproliferative disease (43), the underexpressed tumor suppressor FHIT, the underexpressed double stranded RNA-activated protein kinase proapoptotic PRKR, which upregulates FAS and BAX (44) , and the underexpressed DEFA1 (defensin) involved in immune response.
Having identified genes differentially expressed in ALLs with t(4;11) compared to ALLs without t(4:11), and in AMLs with 11q23 abnormalities compared to AMLs without such abnormalties, we intersected the results of these two tests (we used FDR level of 0.15 for both) in order to find the genes in common. We identified 52 such genes that were overexpressed or downregulated in the relevant tumors ( Fig. 5 and Table 11 in the web site). For all these genes the difference was high for one type of tumors (e.g. ALLs), but modest for the second type (e.g. AMLs). The genes that were overexpressed in the samples with ALL-1 rearrangements included the phosphatase PPP2R5C, and the MCM4 gene whose product is an essential component of the prereplicative complex (45) . The underexpressed genes included FHIT and JUNB.
Discussion
Our results indicate distinct transcription profiles of ALL-1 associated tumors. This is likely to be reflected in the unusual clinical and biological characteristics of these tumors, such as short latency, poor prognosis, expression of myeloid genes in ALL, etc. Some of the genes pinpointed in our study of ALLs with t(4;11), which were mostly adults, were also indicated (Table 3) in our previous preliminary analysis (46) and in recent investigations which dealt with ALLs from infants and children (47, 48) . of genes such as CD44, DHFR and bleomycin hydrolase conferring drug resistance, and overexpression of genes involved in cell prolferation (e.g. cyclin A1 and myb-like 2). Some of the overexpressed genes we identified, like VLDL, PDGFRB, HOX A9, MEIS1 and insulin receptor, are also found expressed in normal hematopoetic stem cells (49) but the majority of genes are not. We suggest that at least some of the genes alluded to by our study contribute directly to the aggressive nature of the disease and to its known resistance to therapy.
In an attempt to identify genes whose expression correlates more strictly with the t(4;11) genotype, we separated away genes which distinguish pro B-from pre B-and T-cell tumors. The resulting list of 46 genes (Table 5 ) includes several oncogenes and tumor suppressor genes and probably constitutes a better database from which to choose genes for further experiments. Another approach taken to identify genes more likely to be associated with the pathogenesis was based on the assumption (still unproven) that ALL-1 fusion proteins trigger malignancy by a similar mechanism in both ALLs and AMLs. Thus, we looked for genes which behave in similar fashion (upregulated or downregulated) in ALLs and AMLs with ALL-1 rearrangements (Fig. 5) . At the top of the list we find PPP2R5C, FHIT and JUNB.
Compartmentalization into two groups of the genes whose expression distinguishes t(4;11) from other ALLs resulted in the unexpected identification of two subclasses of t(4;11) tumors (Fig. 2B) . were not included in the supervised analysis, but were added later for purpose of comparison. 
